Despite the clear association between hyperactivation of the PI3K/Akt/mTOR pathway and poor prognosis in many tumor types, including lung cancer, the efficacy of mTOR inhibitors as monotherapy or in combinations with other targeted therapies is unsatisfactory. Here, MTOR is linked to neoplasm.